Hepatitis B Recurrence After Liver Transplantation: A Single Center Experiences and Review the Literature

Authors Information
Article Notes and Dates
To Cite : Dehghani S M, Taghavi S A R, Geramizadeh B, Nikeghbalian S, Derakhshan N, et al. Hepatitis B Recurrence After Liver Transplantation: A Single Center Experiences and Review the Literature, Hepat Mon. 2013 ;13(1):e6609. doi: 10.5812/hepatmon.6609.
Abstract
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000; 64(1): 51-68[DOI]
  • 2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006; 45(4): 529-38[DOI][PubMed]
  • 3. Riediger C, Berberat PO, Sauer P, Gotthardt D, Weiss KH, Mehrabi A, et al. Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation. Nephrol Dial Transpl. 2007; 22
  • 4. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. The Lancet Infectious Diseases. 2005; 5(9): 558-67[DOI]
  • 5. Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol. 2001; 34(6): 903-10[DOI]
  • 6. Feray C, Samuel D, Thiers V, Gigou M, Pichon F, Bismuth A, et al. Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest. 1992; 89(4): 1361-5[DOI][PubMed]
  • 7. Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl. 2004; 10(8): 968-74[DOI][PubMed]
  • 8. Steinmuller T, Seehofer D, Rayes N, Muller AR, Settmacher U, Jonas S, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology. 2002; 35(6): 1528-35[DOI][PubMed]
  • 9. Vargas HE, Dodson FS, Rakela J. A concise update on the status of liver transplantation for hepatitis B virus: the challenges in 2002. Liver Transpl. 2002; 8(1): 2-9[DOI][PubMed]
  • 10. Weinberger KM, Wiedenmann E, Bohm S, Jilg W. Sensitive and accurate quantitation of hepatitis B virus DNA using a kinetic fluorescence detection system (TaqMan PCR). J Virol Methods. 2000; 85(1-2): 75-82[DOI]
  • 11. Wasmuth J. Hepatology. 2009;
  • 12. Lucey MR, Graham DM, Martin P, Di Bisceglie A, Rosenthal S, Waggoner JG, et al. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut. 1992; 33(10): 1390-6[DOI][PubMed]
  • 13. O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol. 1992; 14(1): 104-11[DOI]
  • 14. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus–related liver disease. Hepatology. 1991; 13(4): 619-26[DOI]
  • 15. McMillan JS, Shaw T, Angus PW, Locarnini SA. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology. 1995; 22(1): 36-43[DOI]
  • 16. Tur-Kaspa R, Shaul Y, Moore DD, Burk RD, Okret S, Poellinger L, et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology. 1988; 167(2): 630-3[DOI]
  • 17. Marzano A, Gaia S, Ghisetti V, Carenzi S, Premoli A, Debernardi-Venon W, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl. 2005; 11(4): 402-9[DOI][PubMed]
  • 18. McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation. 1996; 61(9): 1358-64[DOI][PubMed]
  • 19. Omata M. Significance of extrahepatic replication of hepatitis B virus. Hepatology. 1990; 12(2): 364-6[DOI][PubMed]
  • 20. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993; 329(25): 1842-7[DOI][PubMed]
  • 21. Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl. 2005; 11(7): 716-32[DOI][PubMed]
  • 22. Wang YM, Tang YZ. Antiviral therapy for hepatitis B virus associated hepatic failure. Hepatobiliary Pancreat Dis Int. 2009; 8(1): 17-24[PubMed]
  • 23. Seehofer D, Rayes N, Neuhaus P. Prophylaxis and treatment of hepatitis B recurrence after liver transplantation in the antiviral era. Expert Rev Anti Infect Ther. 2003; 1(2): 307-18[DOI][PubMed]
  • 24. Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Buschenfelde KH, et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology. 1998; 27(1): 254-63[DOI][PubMed]
  • 25. Mutimer D, Pillay D, Dragon E, Tang H, Ahmed M, O'Donnell K, et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol. 1999; 30(4): 715-21[DOI]
  • 26. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007; 45(4): 1056-75[DOI][PubMed]
  • 27. Seehofer D, Rayes N, Berg T, Neuhaus R, Muller AR, Hopf U, et al. Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation. Transpl Int. 2000; 13(4): 290-6[DOI][PubMed]
  • 28. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology. 1998; 28(2): 585-9[DOI][PubMed]
  • 29. Buti M, Mas A, Prieto M, Casafont F, Gonzalez A, Miras M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol. 2003; 38(6): 811-7[DOI]
  • 30. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl. 2000; 6(4): 429-33[DOI][PubMed]
  • 31. Faust D, Rabenau HF, Allwinn R, Caspary WF, Zeuzem S. Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. Clin Transplant. 2003; 17(3): 254-8[DOI][PubMed]
  • 32. Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl. 2000; 6(6): 741-8[DOI][PubMed]
  • 33. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol. 2001; 34(6): 895-902[DOI]
  • 34. Seehofer D, Rayes N, Steinmuller T, Muller AR, Jonas S, Settmacher U, et al. Combination prophylaxis with Hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance. Z Gastroenterol. 2002; 40(9): 795-9[DOI][PubMed]
  • 35. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology. 2000; 32(1): 129-34[DOI][PubMed]
  • 36. Seehofer D, Berg T. Prevention of hepatitis B recurrence after liver transplantation. Transplantation. 2005; 80(1 Suppl)-4[DOI][PubMed]
  • 37. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology. 2003; 125(2): 292-7[DOI]
  • 38. Lai CL, Lim SG, Brown NA, Zhou XJ, Lloyd DM, Lee YM, et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology. 2004; 40(3): 719-26[DOI][PubMed]
  • 39. Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology. 2002; 123(6): 1831-8[DOI][PubMed]
  • 40. van Bommel F, Wunsche T, Schurmann D, Berg T. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology. 2002; 36(2): 507-8[DOI][PubMed]
  • 41. Haberal M, Dalgic A. New concepts in organ transplantation. Transplant Proc. 2004; 36(5): 1219-24[DOI][PubMed]
  • 42. Wu LM, Xu X, Zheng SS. Hepatitis B virus reinfection after liver transplantation: related risk factors and perspective. Hepatobiliary Pancreat Dis Int. 2005; 4(4): 502-8[PubMed]
  • 43. Ying C, De Clercq E, Neyts J. Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus. Antiviral Res. 2000; 48(2): 117-24[DOI]
  • 44. Gong ZJ, De Meyer S, Clarysse C, Verslype C, Neyts J, De Clercq E, et al. Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. J Viral Hepat. 1999; 6(3): 229-36[DOI][PubMed]
  • 45. Wu J, Xie HY, Jiang GP, Xu X, Zheng SS. The role of mycophenolate acid on HBV replication in vitro. Chin J Organ Transplant. 2003; 24: 310-2
  • 46. Liaw YF. Hepatitis viruses under immunosuppressive agents. J Gastroenterol Hepatol. 1998; 13(1): 14-20[DOI][PubMed]
  • 47. Shiota G, Harada K, Oyama K, Udagawa A, Nomi T, Tanaka K, et al. Severe exacerbation of hepatitis after short-term corticosteroid therapy in a patients with "latent" chronic hepatitis B. Liver. 2000; 20(5): 415-20[DOI][PubMed]
  • 48. Samuel D, Kimmoun E. Immunosuppression in hepatitis B virus and hepatitis C virus transplants: special considerations. Clinics in liver disease. 2003; 7(3): 667[DOI]
  • 49. Retrospective analysis of 30 patients who underwent liver transplantation without use of steroids. 1999;
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check